EGI
UTHR icon

EAM Global Investors’s United Therapeutics UTHR Stock Holding History

EAM Global Investors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,344
Closed -$2.04M – 194
2022
Q4 		$2.04M Buy
+7,344
New +$1.85M 0.53% 68
2022
Q3 		– Sell
-11,092
Closed -$2.61M – 250
2022
Q2 		$2.61M Buy
+11,092
New +$2.25M 0.64% 45

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

EAM Global Investors's UTHR Position: Q1 2023 in Review

EAM Global Investors sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 7,344 shares — an estimated $2.04M sold.

EAM Global Investors first reported a position in UTHR in Q2 2022 and held it in 2 quarters. The position peaked at $2.61M in Q2 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • EAM Global Investors reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 7,344 United Therapeutics shares in Q1 2023, an estimated $2.04M.
  • EAM Global Investors first reported a position in United Therapeutics in Q2 2022 and held it in 2 quarters.
  • EAM Global Investors's United Therapeutics position peaked at $2.61M in Q2 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.